PHARMARON BEIJING CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.16 CNY | +5.04% |
|
+5.39% | -33.89% |
| 04-26 | Pharmaron Beijing Posts 34% Profit Drop in Q1 as Revenue Slips 2% | MT |
| 04-26 | Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy | MT |
| Sales 2024 * | 12.76B 1.76B 2.41B | Sales 2025 * | 15.16B 2.09B 2.86B | Capitalization | 30.02B 4.14B 5.66B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.61B 222M 303M | Net income 2025 * | 2.19B 303M 414M | EV / Sales 2024 * | 2.67 x |
| Net Debt 2024 * | 4.01B 553M 756M | Net Debt 2025 * | 2.87B 396M 541M | EV / Sales 2025 * | 2.17 x |
| P/E ratio 2024 * |
19.6
x | P/E ratio 2025 * |
15.6
x | Employees | - |
| Yield 2024 * |
1.01% | Yield 2025 * |
1.42% | Free-Float | 47.74% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +5.04% | ||
| 1 week | +5.39% | ||
| Current month | -5.94% | ||
| 1 month | -8.06% | ||
| 3 months | -12.95% | ||
| 6 months | -30.60% | ||
| Current year | -33.89% |
1 week
17.88
19.16
1 month
17.8821.02
Current year
17.8828.90
1 year
17.8837.00
3 years
17.88108.71
5 years
13.85108.71
10 years
4.08108.71
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Qiang Lou
FOU | Founder | 55 | 04-06-30 |
Bei Zheng
FOU | Founder | 57 | 04-06-30 |
Bo Liang Lou
CEO | Chief Executive Officer | 60 | 04-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kwan Hung Tsang
BRD | Director/Board Member | 60 | 19-08-14 |
Jia Qing Li
BRD | Director/Board Member | 51 | 16-10-26 |
Bo Liang Lou
CEO | Chief Executive Officer | 60 | 04-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.17% | 2 M€ | -16.59% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 19.16 | +5.04% | 35,373,060 |
| 24-04-25 | 18.24 | +0.39% | 20,412,080 |
| 24-04-24 | 18.17 | -1.57% | 18,266,280 |
| 24-04-23 | 18.46 | +1.60% | 23,903,790 |
| 24-04-22 | 18.17 | -0.06% | 17,365,760 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows:
- laboratory services (61.3%);
- development and production of chemical processes and formulations (23.5%);
- clinical research services (12.8%);
- other (2.4%);
Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
19.16
CNY
Average target price
25.3
CNY
Spread / Average Target
+32.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.89% | 4.14B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- 300759 Stock
